Login Shop
Contact Us
Careers Investors Sustainability Vlog

NGL COVID-19 Spike Protein Affinity Resin

Novel SARS CoV-2 specific affinity resin enables a high purity capture step, decreased process time, and yield improvement for the commercial production of COVID-19 vaccines.

Why it matters Related Products
Speak to an Expert
    HIGH PERFORMANCE

SARS CoV-2 specific affinity resin for the purification of COVID-19 vaccines

 

Novel affinity resin for the purification of the SARS CoV-2 Spike Protein for vaccine development and manufacturing

The result of close work with Navigo Proteins on the ligand development and partnership with Purolite Life Sciences on Praesto®agarose bead technology, the new NGL COVID-19 Spike Protein Affinity Resin from Repligen binds the SARS CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. The product meets all the expected requirements of a high-performance resin, including very high selectivity, high dynamic binding capacities and caustic stability over multi-cycle use.

The resin is available in off-the shelf, pre-packed and pre-qualified OPUS® Columns for rapid implementation as well as in loose resin formats.

  HIGH PERFORMANCE

Single-step affinity chromatography with high resolution

NGL COVID-19 Spike Protein Affinity Resin key features include:

  • Single-step purification of SARS-CoV-2 spike protein RBD containing modalities*
  • Compatible with 0.1N NaOH for CIP
  • High binding capacity **
close icon
* Targets SARs CoV-2 spike protein variants containing the RBD. Examples include: S protein (S1/S2), S1 Protein, RBD, S Protein Trimer. Development data suggest that purification of whole inactivated virus, virus like particles (VLPs), and adenovirus may not yield satisfactory results.
**Actual DBC dependent on S protein variant & size
  HIGH PERFORMANCE

Optimized bead chemistry delivers exceptional purity

NGL COVID-19 Spike Protein Affinity Resin delivers >90% purity in one chromatography step.

SDS-PAGE gel of the SARS-CoV-2 Spike protein Receptor Binding Domain (RBD) expressed in HEK293 cells and purified with NGL COVID-19 Spike Protein Affinity Resin.

 SPEED TO MARKET

Available pre-packed in OPUS® Columns for quick deployment

 

The NGL COVID-19 Spike Protein Affinity Resin is available in off-the shelf, pre-packed and pre-qualified OPUS® Columns for rapid GMP implementation as well as in loose resin formats.

OPUS® Columns allow you to progress from development to manufacturing scale in weeks, using pre-packed and pre-qualified chromatography columns.

OPUS® Pre-packed Columns

RGEN

$

Manufacturing Centers of Excellence

Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.

Repligen manufacturing sites are located in Massachusetts, California, and New Jersey in the United States and in Sweden, France, The Netherlands,  Germany and Estonia.

Locations

Customer First.

Support is part of the Repligen DNA. Our goal is to provide exceptional customer experience, and to support the efficient and successful adoption and implementation of all Repligen products and services.

  • Field Application Support
  • Customer Service
  • Field Service Engineers

Have a question?